Clinical Intelligence That Reduces Risk and Improves Revenue in Dermatology
Clintel Strategies translates real-world dermatology practice into actionable insight for investors and life sciences leaders making high-stakes decisions.
Request a Strategic Discussion
WHY DERMATOLOGY DECISIONS MISS THE CLINICAL SIGNAL
Dermatology platforms and therapies succeed or fail based on how care is delivered in practice—not how it is modeled on paper.
Physician associates (PAs) and nurse practitioners (NPs) now deliver the majority of dermatologic care and materially influence adoption, utilization, and persistence of advanced therapies. Yet their real-world behavior is consistently underweighted in investment, diligence, and commercialization decisions.
Clintel exists to close that gap.
WHAT CLINTEL PROVIDES
Independent clinical diligence and risk assessment
Real-world adoption and utilization intelligence
PA/NP-driven workflow and prescribing insight
Decision-ready synthesis for executives, investors, and boards
Clintel does not replace financial, operational, or market analysis—we make them more accurate.
WHO WE SERVE
Private Equity
Underwriting, ownership, and exit clarity for dermatology platforms—grounded in clinical reality.
Biotech & Pharma
Clinical intelligence to ensure dermatologic therapies and innovations succeed in real-world practice.
WHY CLINTEL IS DIFFERENT
Embedded Clinical Reality
Practicing dermatology PA perspective inside PE-backed care delivery.
National Workforce Leadership
President, Society of Dermatology Physician Associates (effective July 1, 2026).
Market-Level Signal
Leading dermatology KOL advisory experience across adoption and utilization.
Investment Translation
MBA-trained clinician bridging clinical, financial, and strategic language.
